AdvanSix Announces Fourth Quarter and Full Year 2025 Financial Results
4Q25 Sales of
4Q25 Earnings Per Share of (
4Q25 Cash Flow from Operations of
2025 planned plant turnarounds completed successfully at lower end of range
Driving improved cash flow in 2026 through fixed cost savings, turnaround scope, risk-based prioritization of capital expenditures, and tax benefits
Full Year 2025 Summary
Summary full year 2025 financial results for the Company are included below:
|
($ in Thousands, Except Earnings Per Share) |
FY 2025 |
|
FY 2024 |
|
Sales |
|
|
|
|
Net Income |
49,286 |
|
44,149 |
|
Diluted Earnings Per Share |
1.80 |
|
1.62 |
|
Adjusted Diluted Earnings Per Share (1) |
2.28 |
|
1.96 |
|
Adjusted EBITDA (1) |
156,798 |
|
142,116 |
|
Adjusted EBITDA Margin % (1) |
10.3% |
|
9.4% |
|
Cash Flow from Operations |
122,863 |
|
135,413 |
|
Capital Expenditures |
116,445 |
|
133,722 |
|
Free Cash Flow (1)(2) |
6,418 |
|
1,691 |
|
(1) See “Non-GAAP Measures” included in this press release for non-GAAP reconciliations |
|
(2) Net cash provided by operating activities less capital expenditures |
Sales by product line and approximate percentage of total sales are included below:
|
($ in Thousands) |
FY 2025 |
|
FY 2024 (1) |
||||||
|
|
Sales |
|
% of Total |
|
Sales |
|
% of Total |
||
|
Nylon |
$ |
309,678 |
|
20% |
|
$ |
348,501 |
|
23% |
|
Caprolactam |
|
271,370 |
|
18% |
|
|
276,303 |
|
18% |
|
Plant Nutrients |
|
563,688 |
|
37% |
|
|
458,152 |
|
30% |
|
Chemical Intermediates |
|
377,497 |
|
25% |
|
|
434,601 |
|
29% |
|
Total |
$ |
1,522,233 |
|
100% |
|
$ |
1,517,557 |
|
100% |
|
(1) In 2024, the Company transferred certain products between its Chemical Intermediates product line and its Plant Nutrients product line to align more closely with its current sales structure. Historical information has been reclassified to reflect these changes for all periods presented in the Consolidated Financial Statements. Total revenue amounts were not impacted for either period. |
"The
Fourth Quarter 2025 Summary
Summary fourth quarter 2025 financial results for the Company are included below:
|
($ in Thousands, Except Earnings Per Share) |
4Q 2025 |
|
4Q 2024 |
|
Sales |
|
|
|
|
Net Income (loss) |
(2,791) |
|
352 |
|
Diluted Earnings Per Share |
(0.10) |
|
0.01 |
|
Adjusted Diluted Earnings Per Share (1) |
0.03 |
|
0.09 |
|
Adjusted EBITDA (1) |
24,763 |
|
10,219 |
|
Adjusted EBITDA Margin % (1) |
6.9% |
|
3.1% |
|
Cash Flow from Operations |
63,722 |
|
64,165 |
|
Capital Expenditures |
27,596 |
|
34,349 |
|
Free Cash Flow (1)(2) |
36,126 |
|
29,816 |
|
(1) See “Non-GAAP Measures” included in this press release for non-GAAP reconciliations |
|
(2) Net cash provided by operating activities less capital expenditures |
Sales of
Sales by product line and approximate percentage of total sales are included below:
|
($ in Thousands) |
4Q 2025 |
|
4Q 2024 (1) |
||||||
|
|
Sales |
|
% of Total |
|
Sales |
|
% of Total |
||
|
Nylon |
$ |
62,778 |
|
17% |
|
$ |
67,172 |
|
21% |
|
Caprolactam |
|
64,377 |
|
18% |
|
|
57,216 |
|
17% |
|
Plant Nutrients |
|
139,991 |
|
39% |
|
|
102,566 |
|
31% |
|
Chemical Intermediates |
|
92,801 |
|
26% |
|
|
102,109 |
|
31% |
|
Total |
$ |
359,947 |
|
100% |
|
$ |
329,063 |
|
100% |
|
(1) In 2024, the Company transferred certain products between its Chemical Intermediates product line and its Plant Nutrients product line to align more closely with its current sales structure. Historical information has been reclassified to reflect these changes for all periods presented in the Consolidated Financial Statements. Total revenue amounts were not impacted for either period. |
Adjusted EBITDA of
Adjusted earnings per share of
Cash flow from operations of
Outlook
- Anticipate continued strength in Plant Nutrients supply and demand fundamentals amid meaningfully higher sulfur input costs
-
Acetone spread over propylene costs expected to hold near cycle averages; Anti-dumping duties into
U.S. renewed for another five years - Navigating an extended trough in the nylon cycle - focused on controllable levers to optimize performance
-
Expect Capital Expenditures of
$75 to$95 million in 2026 versus approximately$116 million in 2025, reflecting a risk-based prioritization of base investments and enterprise programs with continued progression of growth programs including SUSTAIN -
Expect pre-tax income impact of plant turnarounds to be
$20 to$25 million in 2026 versus approximately$25 million in 2025 - Expect cash flow benefit in 2026 and beyond from 45Q carbon capture tax credits and 100% bonus depreciation
"The end market environment entering 2026 remains mixed overall. We've seen continued strength in Plant Nutrients and acetone margins remain near cycle averages, while nylon has plateaued in its trough. Conversely, there have been several recent industry announcements pointing to capacity rationalization and lower operating rates, which we believe should lead to more favorable supply and demand conditions over time. We remain highly focused on delivering on controllable levers including continued optimization of production output and sales volume mix while driving productivity to support through-cycle profitability. We have embarked on a multi-year non-manpower fixed cost savings program targeting approximately
Dividend
The Company's Board of Directors declared a quarterly cash dividend of
Conference Call Information
About
Forward Looking Statements
This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, that address activities, events or developments that our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements may be identified by words such as "expect," "anticipate," "estimate," “outlook,” "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should" and "believe" and other variations or similar terminology and expressions. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the
Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures intended to supplement, not to act as substitutes for, comparable GAAP measures. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. Non-GAAP measures in this press release may be calculated in a way that is not comparable to similarly-titled measures reported by other companies.
|
Consolidated Balance Sheets (Unaudited) (Dollars in thousands, except share and per share amounts) |
|||||||
|
|
|
|
|
||||
|
ASSETS |
|
|
|
||||
|
Current assets: |
|
|
|
||||
|
Cash and cash equivalents |
$ |
19,766 |
|
|
$ |
19,564 |
|
|
Accounts and other receivables – net |
|
154,102 |
|
|
|
145,673 |
|
|
Inventories – net |
|
236,495 |
|
|
|
212,386 |
|
|
Taxes receivable |
|
21,605 |
|
|
|
503 |
|
|
Other current assets |
|
8,639 |
|
|
|
8,990 |
|
|
Total current assets |
|
440,607 |
|
|
|
387,116 |
|
|
Property, plant and equipment – net |
|
963,718 |
|
|
|
917,858 |
|
|
Operating lease right-of-use assets |
|
164,494 |
|
|
|
153,438 |
|
|
|
|
56,192 |
|
|
|
56,192 |
|
|
Intangible assets |
|
40,095 |
|
|
|
43,144 |
|
|
Other assets |
|
41,042 |
|
|
|
37,172 |
|
|
Total assets |
$ |
1,706,148 |
|
|
$ |
1,594,920 |
|
|
|
|
|
|
||||
|
LIABILITIES |
|
|
|
||||
|
Current liabilities: |
|
|
|
||||
|
Accounts payable |
$ |
284,016 |
|
|
$ |
228,761 |
|
|
Accrued liabilities |
|
45,945 |
|
|
|
47,264 |
|
|
Income taxes payable |
|
1,100 |
|
|
|
1,047 |
|
|
Operating lease liabilities – short-term |
|
44,354 |
|
|
|
42,493 |
|
|
Deferred income and customer advances |
|
14,536 |
|
|
|
37,538 |
|
|
Total current liabilities |
|
389,951 |
|
|
|
357,103 |
|
|
Deferred income taxes |
|
154,061 |
|
|
|
145,299 |
|
|
Operating lease liabilities – long-term |
|
121,201 |
|
|
|
111,400 |
|
|
Line of credit – long-term |
|
215,000 |
|
|
|
195,000 |
|
|
Other liabilities |
|
10,719 |
|
|
|
11,468 |
|
|
Total liabilities |
|
890,932 |
|
|
|
820,270 |
|
|
|
|
|
|
||||
|
STOCKHOLDERS' EQUITY |
|
|
|
||||
|
Common stock, par value |
|
332 |
|
|
|
330 |
|
|
Preferred stock, par value |
|
— |
|
|
|
— |
|
|
|
|
(63 |
) |
|
|
(63 |
) |
|
Additional paid-in capital |
|
142,932 |
|
|
|
136,872 |
|
|
Retained earnings |
|
663,019 |
|
|
|
631,541 |
|
|
Accumulated other comprehensive income |
|
8,996 |
|
|
|
5,970 |
|
|
Total stockholders' equity |
|
815,216 |
|
|
|
774,650 |
|
|
Total liabilities and stockholders' equity |
$ |
1,706,148 |
|
|
$ |
1,594,920 |
|
|
Consolidated Statements of Operations (Unaudited) (Dollars in thousands, except share and per share amounts) |
||||||||||||||
|
|
Three Months Ended
|
|
Twelve Months Ended
|
|||||||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Sales |
$ |
359,947 |
|
|
$ |
329,063 |
|
|
$ |
1,522,233 |
|
|
$ |
1,517,557 |
|
|
|
|
|
|
|
|
|
|||||||
|
Costs, expenses and other: |
|
|
|
|
|
|
|
|||||||
|
Cost of goods sold |
|
332,576 |
|
|
|
317,762 |
|
|
|
1,357,293 |
|
|
|
1,364,621 |
|
Selling, general and administrative expenses |
|
28,499 |
|
|
|
21,734 |
|
|
|
104,750 |
|
|
|
94,023 |
|
Interest expense, net |
|
2,363 |
|
|
|
2,174 |
|
|
|
8,481 |
|
|
|
11,311 |
|
Other non-operating (income) expense, net |
|
(890 |
) |
|
|
218 |
|
|
|
(2,722 |
) |
|
|
2,027 |
|
Total costs, expenses and other |
|
362,548 |
|
|
|
341,888 |
|
|
|
1,467,802 |
|
|
|
1,471,982 |
|
|
|
|
|
|
|
|
|
|||||||
|
Income (loss) before taxes |
|
(2,601 |
) |
|
|
(12,825 |
) |
|
|
54,431 |
|
|
|
45,575 |
|
Income tax expense (benefit) |
|
190 |
|
|
|
(13,177 |
) |
|
|
5,145 |
|
|
|
1,426 |
|
Net income (loss) |
$ |
(2,791 |
) |
|
$ |
352 |
|
|
$ |
49,286 |
|
|
$ |
44,149 |
|
|
|
|
|
|
|
|
|
|||||||
|
Earnings per common share |
|
|
|
|
|
|
|
|||||||
|
Basic |
$ |
(0.10 |
) |
|
$ |
0.01 |
|
|
$ |
1.83 |
|
|
$ |
1.65 |
|
Diluted |
$ |
(0.10 |
) |
|
$ |
0.01 |
|
|
$ |
1.80 |
|
|
$ |
1.62 |
|
|
|
|
|
|
|
|
|
|||||||
|
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|||||||
|
Basic |
|
26,941,274 |
|
|
|
26,805,182 |
|
|
|
26,901,046 |
|
|
|
26,828,338 |
|
Diluted |
|
26,941,274 |
|
|
|
27,234,784 |
|
|
|
27,327,449 |
|
|
|
27,255,213 |
|
Consolidated Statements of Cash Flows (Unaudited) (Dollars in thousands) |
|||||||||||||||
|
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
||||||||
|
Net income (loss) |
$ |
(2,791 |
) |
|
$ |
352 |
|
|
$ |
49,286 |
|
|
$ |
44,149 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
||||||||
|
Depreciation and amortization |
|
20,774 |
|
|
|
18,979 |
|
|
|
79,740 |
|
|
|
76,176 |
|
|
(Gain) loss on disposal of assets |
|
96 |
|
|
|
358 |
|
|
|
(81 |
) |
|
|
773 |
|
|
Deferred income taxes |
|
(6,645 |
) |
|
|
(12,629 |
) |
|
|
7,821 |
|
|
|
(8,991 |
) |
|
Stock-based compensation |
|
902 |
|
|
|
1,891 |
|
|
|
6,821 |
|
|
|
7,854 |
|
|
Amortization of deferred financing fees |
|
133 |
|
|
|
154 |
|
|
|
597 |
|
|
|
618 |
|
|
Operational asset adjustments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,200 |
|
|
Changes in assets and liabilities, net of business acquisitions: |
|
|
|
|
|
|
|
||||||||
|
Accounts and other receivables |
|
30,576 |
|
|
|
3,342 |
|
|
|
(8,395 |
) |
|
|
18,411 |
|
|
Inventories |
|
(27,375 |
) |
|
|
1,048 |
|
|
|
(24,109 |
) |
|
|
(555 |
) |
|
Taxes receivable |
|
2,153 |
|
|
|
(128 |
) |
|
|
(21,102 |
) |
|
|
931 |
|
|
Accounts payable |
|
36,320 |
|
|
|
13,077 |
|
|
|
52,866 |
|
|
|
(30,610 |
) |
|
Income taxes payable |
|
1,051 |
|
|
|
612 |
|
|
|
53 |
|
|
|
(6,986 |
) |
|
Accrued liabilities |
|
(9,721 |
) |
|
|
(8,562 |
) |
|
|
(808 |
) |
|
|
2,426 |
|
|
Deferred income and customer advances |
|
13,855 |
|
|
|
36,021 |
|
|
|
(23,002 |
) |
|
|
21,860 |
|
|
Other assets and liabilities |
|
4,394 |
|
|
|
9,650 |
|
|
|
3,176 |
|
|
|
8,157 |
|
|
Net cash provided by operating activities |
|
63,722 |
|
|
|
64,165 |
|
|
|
122,863 |
|
|
|
135,413 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
||||||||
|
Expenditures for property, plant and equipment |
|
(27,596 |
) |
|
|
(34,349 |
) |
|
|
(116,445 |
) |
|
|
(133,722 |
) |
|
Other investing activities |
|
(16 |
) |
|
|
(3,127 |
) |
|
|
(6,169 |
) |
|
|
(9,180 |
) |
|
Net cash used for investing activities |
|
(27,612 |
) |
|
|
(37,476 |
) |
|
|
(122,614 |
) |
|
|
(142,902 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
||||||||
|
Borrowings from line of credit |
|
54,000 |
|
|
|
94,500 |
|
|
|
370,500 |
|
|
|
406,000 |
|
|
Repayments of line of credit |
|
(89,000 |
) |
|
|
(114,500 |
) |
|
|
(350,500 |
) |
|
|
(381,000 |
) |
|
Payment of line of credit facility fees |
|
(478 |
) |
|
|
— |
|
|
|
(478 |
) |
|
|
— |
|
|
Principal payments of finance leases |
|
(262 |
) |
|
|
(249 |
) |
|
|
(1,002 |
) |
|
|
(1,011 |
) |
|
Dividend payments |
|
(4,300 |
) |
|
|
(4,277 |
) |
|
|
(17,176 |
) |
|
|
(17,135 |
) |
|
Purchase of treasury stock |
|
— |
|
|
|
(1 |
) |
|
|
(1,658 |
) |
|
|
(10,428 |
) |
|
Issuance of common stock |
|
— |
|
|
|
104 |
|
|
|
267 |
|
|
|
859 |
|
|
Net cash used for financing activities |
|
(40,040 |
) |
|
|
(24,423 |
) |
|
|
(47 |
) |
|
|
(2,715 |
) |
|
|
|
|
|
|
|
|
|
||||||||
|
Net change in cash and cash equivalents |
|
(3,930 |
) |
|
|
2,266 |
|
|
|
202 |
|
|
|
(10,204 |
) |
|
Cash and cash equivalents at beginning of period |
|
23,696 |
|
|
|
17,298 |
|
|
|
19,564 |
|
|
|
29,768 |
|
|
Cash and cash equivalents at the end of period |
$ |
19,766 |
|
|
$ |
19,564 |
|
|
$ |
19,766 |
|
|
$ |
19,564 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Supplemental non-cash investing activities: |
|
|
|
|
|
|
|
||||||||
|
Capital expenditures included in accounts payable |
|
|
|
|
$ |
26,670 |
|
|
$ |
23,645 |
|
||||
|
Non-GAAP Measures (Dollars in thousands, except share and per share amounts)
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow |
|||||||||||||||
|
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
Net cash provided by operating activities |
$ |
63,722 |
|
|
$ |
64,165 |
|
|
$ |
122,863 |
|
|
$ |
135,413 |
|
|
Expenditures for property, plant and equipment |
|
(27,596 |
) |
|
|
(34,349 |
) |
|
|
(116,445 |
) |
|
|
(133,722 |
) |
|
Free cash flow (1) |
$ |
36,126 |
|
|
$ |
29,816 |
|
|
$ |
6,418 |
|
|
$ |
1,691 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
(1) Free cash flow is a non-GAAP measure defined as Net cash provided by operating activities less Expenditures for property, plant and equipment. |
|||||||||||||||
|
The Company believes that this metric is useful to investors and management as a measure to evaluate our ability to generate cash flow from business operations and the impact that this cash flow has on our liquidity. |
|||||||||||||||
| Reconciliation of Net Income to Adjusted EBITDA and Earnings Per Share to Adjusted Earnings Per Share | |||||||||||||||
|
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
|
Net income (loss) |
$ |
(2,791 |
) |
|
$ |
352 |
|
|
$ |
49,286 |
|
|
$ |
44,149 |
|
|
Non-cash stock-based compensation |
|
902 |
|
|
|
1,891 |
|
|
|
6,821 |
|
|
|
7,854 |
|
|
Non-recurring, unusual or extraordinary expense (2) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,200 |
|
|
Non-cash amortization from acquisitions |
|
532 |
|
|
|
531 |
|
|
|
2,127 |
|
|
|
2,126 |
|
|
Strategic advisory and professional fees (3) |
|
3,325 |
|
|
|
— |
|
|
|
7,325 |
|
|
|
— |
|
|
Income tax benefit relating to reconciling items |
|
(1,099 |
) |
|
|
(417 |
) |
|
|
(3,386 |
) |
|
|
(2,011 |
) |
|
Adjusted Net income (non-GAAP) |
|
869 |
|
|
|
2,357 |
|
|
|
62,173 |
|
|
|
53,318 |
|
|
Interest expense, net |
|
2,363 |
|
|
|
2,174 |
|
|
|
8,481 |
|
|
|
11,311 |
|
|
Income tax expense (benefit) - Adjusted |
|
1,289 |
|
|
|
(12,760 |
) |
|
|
8,531 |
|
|
|
3,437 |
|
|
Depreciation and amortization - Adjusted |
|
20,242 |
|
|
|
18,448 |
|
|
|
77,613 |
|
|
|
74,050 |
|
|
Adjusted EBITDA (non-GAAP) |
$ |
24,763 |
|
|
$ |
10,219 |
|
|
$ |
156,798 |
|
|
$ |
142,116 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Sales |
$ |
359,947 |
|
|
$ |
329,063 |
|
|
$ |
1,522,233 |
|
|
$ |
1,517,557 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
Adjusted EBITDA Margin (non-GAAP) (4) |
|
6.9 |
% |
|
|
3.1 |
% |
|
|
10.3 |
% |
|
|
9.4 |
% |
|
|
|
|
|
|
|
|
|
||||||||
|
(2) 2024 includes a pre-tax loss of approximately |
|||||||||||||||
|
(3) Legal and professional fees associated with strategic regulatory matters and potential inorganic growth options, including costs associated with a transaction the Company is no longer pursuing |
|||||||||||||||
|
(4) Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales |
|||||||||||||||
|
|
Three Months Ended
|
|
Twelve Months Ended
|
|||||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Net income (loss) |
$ |
(2,791 |
) |
|
$ |
352 |
|
$ |
49,286 |
|
$ |
44,149 |
|
Adjusted Net income (non-GAAP) |
|
869 |
|
|
|
2,357 |
|
|
62,173 |
|
|
53,318 |
|
|
|
|
|
|
|
|
|
|||||
|
Weighted-average number of common shares outstanding - basic |
|
26,941,274 |
|
|
|
26,805,182 |
|
|
26,901,046 |
|
|
26,828,338 |
|
Dilutive effect of equity awards and other stock-based holdings |
|
— |
|
|
|
429,602 |
|
|
426,403 |
|
|
426,875 |
|
Weighted-average number of common shares outstanding - diluted |
|
26,941,274 |
|
|
|
27,234,784 |
|
|
27,327,449 |
|
|
27,255,213 |
|
|
|
|
|
|
|
|
|
|||||
|
EPS - Basic |
$ |
(0.10 |
) |
|
$ |
0.01 |
|
$ |
1.83 |
|
$ |
1.65 |
|
EPS - Diluted |
$ |
(0.10 |
) |
|
$ |
0.01 |
|
$ |
1.80 |
|
$ |
1.62 |
|
Adjusted EPS - Basic (non-GAAP) |
$ |
0.03 |
|
|
$ |
0.09 |
|
$ |
2.31 |
|
$ |
1.99 |
|
Adjusted EPS - Diluted (non-GAAP) |
$ |
0.03 |
|
|
$ |
0.09 |
|
$ |
2.28 |
|
$ |
1.96 |
|
The Company believes the non-GAAP financial measures presented in this release provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s operating performance, enhance a reader’s understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as these non-GAAP measures exclude items that are not considered core to the Company’s operations. |
|
Appendix (Pre-tax income impact, Dollars in millions)
Planned Plant Turnaround Schedule (4) |
||||||||||||
|
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
Primary Unit Operation |
|
|
2017 |
— |
|
|
|
|
|
|
|
|
|
Sulfuric Acid |
|
|
2018 |
|
|
|
|
|
|
— |
|
|
|
Ammonia |
|
|
2019 |
— |
|
|
|
|
|
|
|
|
|
Sulfuric Acid |
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
Ammonia |
|
|
2021 |
|
|
|
|
— |
|
|
|
|
|
Sulfuric Acid |
|
|
2022 |
|
|
|
|
|
|
— |
|
|
|
Ammonia |
|
|
2023 |
|
|
|
|
|
|
— |
|
|
|
Sulfuric Acid |
|
|
2024 |
|
|
|
|
|
|
|
|
|
|
Ammonia |
|
|
2025 |
|
|
|
|
— |
|
|
|
|
|
Sulfuric Acid |
|
|
2026E |
|
|
|
|
— |
|
|
|
|
|
Ammonia |
|
|
(4) Primarily reflects the impact of fixed cost absorption, maintenance expense, and the purchase of feedstocks which are normally manufactured by the Company. |
|
(5) During the multi-site planned plant turnaround, additional required maintenance at our Frankford phenol plant contributed to reduced production across our integrated value chain and a delayed ramp to full operating rates at our |
|
(6) During the multi-site planned plant turnaround, additional required maintenance at our |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219417617/en/
Media
(973) 526-1615
janeen.lawlor@advansix.com
Investors
(973) 526-1700
adam.kressel@advansix.com
Source: